The brokerage highlighted Sagility India's position as a leading US-healthcare-focused BPM firm with deep domain expertise. The firm expects the company to achieve a revenue CAGR of 12% and a profit CAGR of 40% between FY25 and FY27, supporting its current P/E multiples. ' The broker noted several factors driving Sagility's growth, including sustained double-digit revenue growth, normalization of depreciation and amortization (D&A) costs, and debt reduction efforts, which are expected to boost EPS. Sagility India provides technology-enabled business solutions and services to clients in the US healthcare industry. It is a pure-play healthcare focused services provider, and its clients include payers (US. health insurance companies, which finance and reimburse the cost of health services) and providers (primarily hospitals, physicians, and diagnostic and medical devices companies). The company's consolidated net profit surged 235.64% to Rs 117.34 crore on 21.10% rise in revenue from operations to Rs 1,325 crore in Q2 FY25 over Q2 FY24. Sagility India made its stock market debut on 12 November 2024. The stock listed at Rs 31.06, a premium of 3.53% over its issue price of Rs 30. The IPO, which was open for subscription from November 5 to 7, 2024, was oversubscribed 3.20 times. Powered by Capital Market - Live

Net profit of Sagility India rose 235.64% to Rs 117.34 crore in the quarter ended September 2024 as against Rs 34.96 crore during the previous quarter ended September 2023. Sales rose 21.11% to Rs 1325.05 crore in the quarter ended September 2024 as against Rs 1094.10 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales1325.051094.10 21 OPM %22.7321.40 - PBDT286.78214.85 33 PBT160.4243.38 270 NP117.3434.96 236 Powered by Capital Market - Live

The domestic equity benchmarks traded with modest losses in the early afternoon trade. The Nifty slipped below the 23,150 mark after hitting the day's high of 24,343.30 in early trade. Auto shares declined after advancing in past two consecutive trading sessions. At 12:30 IST, the barometer index, the S&P BSE Sensex, was down 269.80 points or 0.34% to 79,840.05. The Nifty 50 index lost 77.80 points or 0.32% to 24,144.10. The broader market outperformed the benchmark indices. The S&P BSE Mid-Cap index gained 0.26% and the S&P BSE Small-Cap index added 0.40%. The market breadth was strong. On the BSE, 2,181 shares rose and 1,571 shares fell. A total of 157 shares were unchanged. Derivatives: The NSE's India VIX, a gauge of the market's expectation of volatility over the near term, rose 1.96% to 15.60. The Nifty 28 November 2024 futures were trading at 24,172.30, at a premium of 28.20 points as compared with the spot at 24,144.10. The Nifty option chain for the 28 November 2024 expiry showed maximum Call OI of 110.8 lakh contracts at the 25,000 strike price. Maximum Put OI of 95.8 lakh contracts were seen at 23,000 strike price. Buzzing Index: The Nifty Auto index slipped 1.18% to 23,437.70. The index rallied 2.64% in past two consecutive trading sessions. Bajaj Auto (down 2.93%), Mahindra & Mahindra (down 1.9%), Eicher Motors (down 1.86%), TVS Motor Company (down 1.36%), Tata Motors (down 0.88%), Ashok Leyland (down 0.69%), Maruti Suzuki India (down 0.46%) and Hero MotoCorp (down 0.38%) declined. On the other hand, Apollo Tyres (up 2.46%), Balkrishna Industries (up 0.94%) and Samvardhana Motherson International (up 0.70%) edged higher. Stocks in Spotlight: Sagility India zoomed 9.98% after the company's consolidated net profit surged 235.64% to Rs 117.34 crore on 21.10% rise in revenue from operations to Rs 1,325 crore in Q2 FY25 over Q2 FY24. Kwality Pharmaceuticals advanced 2.57% after the company announced that it has successfully received domestic and export product approvals for the manufacturing and sale of its biological product, PEGylated-Asparaginase. Zomato added 1.08% after the company's board has approved the opening of qualified institutional placement (QIP) of equity shares with the floor price of Rs 265.91 per share. Further, the food delivery company informed that it has received communication regarding liquidation of Zomato Internet LLC (ZIL), a step down subsidiary of Zomato effective from 20 November 2024. It had already disclosed in red herring prospectus dated 6 July 2021 and prospectus dated 19 July 2021 that ZIL didn't have any active business operations and was under the process of liquidation. Powered by Capital Market - Live

Profit before tax was at Rs 160.42 crore in the second quarter of FY25, marking a growth of 269.88% as against Rs 43.37 crore posted in Q2 FY24. Total expenses rose 9.27% year on year to Rs 1,180 crore during the quarter. Employee benefits expense stood at Rs 812.43 crore (up 19.38% YoY) and finance cost stood at Rs 29.70 crore (down 38.49% YoY) in Q2 FY25. On half year basis, the company's net profit spiked 80.27% to Rs 139.64 crore on 15.30% increased in revenue from operations to Rs 2,548.4 crore in H1 FY25 over H1 FY24. Ramesh Gopalan, MD and Group CEO said, 'Sagility occupies a critical position in the US healthcare services space, supported by domain expertise and long-standing client relationships. Over the years we have built tech enabled solutions and services to deliver best-in-class business outcomes for Payers and Providers, resulting in continued accretion to size and duration of our client engagements. Our runway for growth is long and is backed by a combination of favorable industry dynamics, our strategic investments in advanced technologies including AI and a strong orientation towards creating value for our clients.' Sarvabhouman Srinivasan, Group CFO added, 'Our EBITDA margin is consistent with our historical performance, and we will continue to make investments in technology, AI use cases to deliver superior outcomes and create value for our stakeholders.' Sagility India provides technology-enabled business solutions and services to clients in the US healthcare industry. It is a pure-play healthcare focused services provider, and its clients include payers (US. health insurance companies, which finance and reimburse the cost of health services) and providers (primarily hospitals, physicians, and diagnostic and medical devices companies).Powered by Capital Market - Live

Sagility India will hold a meeting of the Board of Directors of the Company on 25 November 2024Powered by Capital Market - Live

The scrip was listed at Rs 31.06, exhibiting a premium of 3.53% to the issue price. So far, the stock has hit a high of 32.60 and a low of 30.51. On the BSE, over 66.75 lakh shares of the company were traded in the counter so far. The initial public offer (IPO) of Sagility India was subscribed 3.20 times. The issue opened for bidding on 5 November 2024 and it closed on 7 November 2024. The price band of the IPO was fixed between Rs 28 to 30 per share. The IPO comprised only a offer for sale up to 70,21,99,262 shares by the selling shareholder, Sagility BV (Holding company). The company did not receive any proceeds from the offer and all the proceeds was received by the selling shareholders. Ahead of the IPO, Sagility India on Monday, 4 November 2024, raised Rs 945.40 crore from anchor investors. The board allotted 31.51 crore shares at Rs 30 each to 52 anchor investors. Sagility India provides technology-enabled business solutions and services to clients in the US healthcare industry. It is a pure-play healthcare focused services provider, and its clients include payers (US. health insurance companies, which finance and reimburse the cost of health services) and providers (primarily hospitals, physicians, and diagnostic and medical devices companies). Sagility supports the core business of both payers and providers. Services to payers span their entire operational spectrum, including centralized claims administration and clinical services functions. These include claims administration, payment integrity, clinical management and other services. The firm reported a consolidated net profit of Rs 22.29 crore and sales of Rs 1,223.33 crore for the three months ended on 30 June 2024. Powered by Capital Market - Live

The initial public offer (IPO) of Sagility India received 1,24,00,17,000 bids for shares as against 38,70,64,594 shares on offer. The issue was subscribed 3.20 times. The Retail Individual Investors (RIIs) category was subscribed 4.16 times. The Qualified Institutional Buyers (QIBs) category was subscribed 3.52 times. The Non-Institutional Investors (NIIs) category was subscribed 1.93 times. The issue opened for bidding on 5 November 2024 and it closed on 7 November 2024. The price band of the IPO was fixed between Rs 28 to 30 per share. The IPO comprises only a offer for sale up to 70,21,99,262 shares by the selling shareholder, Sagility BV (Holding company). The company will not receive any proceeds from the offer and all the proceeds will be received by the selling shareholders. Ahead of the IPO, Sagility India on Monday, 4 November 2024, raised Rs 945.40 crore from anchor investors. The board allotted 31.51 crore shares at Rs 30 each to 52 anchor investors. Sagility India provides technology-enabled business solutions and services to clients in the US healthcare industry. It is a pure-play healthcare focused services provider, and its clients include payers (US. health insurance companies, which finance and reimburse the cost of health services) and providers (primarily hospitals, physicians, and diagnostic and medical devices companies). Sagility supports the core business of both payers and providers. Services to payers span their entire operational spectrum, including centralized claims administration and clinical services functions. These include claims administration, payment integrity, clinical management and other services. The firm reported a consolidated net profit of Rs 22.29 crore and sales of Rs 1,223.33 crore for the three months ended on 30 June 2024. Powered by Capital Market - Live